Abstract:Background: The chromodomain helicase DNA-binding protein 2 (CHD2) gene, is an ATPase and part of the CHD family of chromatin remodelers. Mutations in the CHD2 gene are inherited in an autosomal-dominant manner and can lead to intellectual disability, epilepsy, and autism. We investigated the clinical characteristics of CHD2-related conditions and their possible pathogenesis. Methods: We collected and analysed the clinical data of patients that were identified as having CHD2 mutations. Genetic testing was performed using targeted sequencing or whole-exome sequencing. We analysed the expression of CHD2 and repressor element 1-silencing transcription factor (REST) in blood samples using quantitative PCR and the conservation of the mutations. The CHD2 mutations we identified were compared with the known mutations reported in the CHD2-related literature. Results: Eight patients with CHD2 gene mutations were analysed. Six mutations were identified; four were unreported previously (c.670C>T; c.4012A>C; c.2416dup; c.1727-1728insAT), and two were known mutations: c.5035C>T (two cases) and c.4173dup (two cases). Among these mutations, seven were de novo mutations, and one could not be determined because the parents refused genetic testing. The clinical manifestations included mild or severe intellectual disability, epilepsy, and behavioural abnormalities. Quantitative PCR showed that the CHD2 gene expression levels among the patients, parents, and the controls were not significantly different. The levels of REST gene expression in the patients were significantly higher than those of the controls; thus, mutation of the CHD2 gene led to an increase in the expression level of the REST gene. The mutations reported were all located in conserved positions in different species. Among the various medications administered for treatment, valproate showed the best results for the treatment of epilepsy caused by CHD2 gene mutation. Conclusion: Mutation in CHD2 did not lead to a significant decrease in its expression level, indicating that the clinical phenotype was unrelated to its expression level, and the mutant protein may retain some function. Most of the mutations relatively stable. In addition, the clinical manifestations from the same mutation in the CHD2 gene were different among the known cases; this may be related to the regulation of REST or other regulatory factors.

Expanding the Mutational Landscape and Clinical Phenotype of CHD2-Related Encephalopathy

Clinical Study of 8 Cases of CHD2 Gene Mutation-Related Neurological Diseases and Their Mechanisms

A Novel Variant of the CHD2 Gene Associated With Developmental Delay and Myoclonic Epilepsy

Clinical Study of 8 Cases of <i>CHD2</i> Gene Mutation-Related Neurological Diseases and Their Mechanisms

CHD2-Related CNS Pathologies

CHD2 haploinsufficiency is associated with developmental delay, intellectual disability, epilepsy and neurobehavioural problems

Clinical analysis of five CHD2 gene mutations in Chinese children with epilepsy

CHD2‐related Epilepsy: Novel Mutations and New Phenotypes

Clinical analysis of CHD2 gene mutations in pediatric patients with epilepsy

A novel de novo frameshift variant in the CHD2 gene related to intellectual and developmental disability, seizures and speech problems

Novel Loss-of-Function Variants in CHD2 Cause Childhood-Onset Epileptic Encephalopathy in Chinese Patients

Mono and biallelic variants in cause severe neurodevelopmental disorders

CHD2‐related epilepsy with eyelid myoclonia: Report of three cases

Clinical features and genotype-phenotype correlations in epilepsy patients with de novo DYNC1H1 variants

Exploring the clinical spectrum of CNTNAP2-related neurodevelopmental disorders: A case series and a literature appraisal

CHD2 mutations in Lennox-Gastaut syndrome

Encephalopathies with KCNC1 variants: genotype-phenotype-functional correlations

KCNT2-Related Disorders: Phenotypes, Functional, and Pharmacological Properties

Case Report: Causative De Novo Variants of KCNT2 for Developmental and Epileptic Encephalopathy

CHD2 pathogenic nonsense variant in a three-generation family with variable phenotype and a paracentric inversion 16: Case report

Diagnostic utility of DNA methylation analysis in genetically unsolved pediatric epilepsies and CHD2 episignature refinement